Daily Stock Analysis, RGNX, Regenxbio Inc, priceseries

Regenxbio Inc. Daily Stock Analysis
Stock Information
Open
27.40
Close
27.53
High
28.07
Low
26.87
Previous Close
27.60
Daily Price Gain
-0.07
YTD High
34.46
YTD High Date
Jan 4, 2022
YTD Low
24.09
YTD Low Date
Feb 24, 2022
YTD Price Change
-6.78
YTD Gain
-19.76%
52 Week High
46.46
52 Week High Date
Sep 14, 2021
52 Week Low
24.09
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-11.75
52 Week Gain
-29.91%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 27. 2017
18.20
Mar 16. 2017
20.04
13 Trading Days
10.13%
Link
LONG
Apr 12. 2017
18.80
May 2. 2017
20.21
13 Trading Days
7.53%
Link
LONG
Aug 30. 2017
21.10
Oct 10. 2017
31.46
28 Trading Days
49.10%
Link
LONG
Dec 15. 2017
29.25
Jan 5. 2018
30.75
13 Trading Days
5.13%
Link
LONG
Mar 7. 2018
37.50
Mar 8. 2018
39.75
1 Trading Days
6.00%
Link
LONG
Jun 18. 2018
57.00
Jul 12. 2018
75.95
17 Trading Days
33.24%
Link
LONG
Sep 13. 2018
73.60
Sep 17. 2018
77.50
2 Trading Days
5.30%
Link
LONG
Oct 30. 2018
61.96
Nov 9. 2018
67.81
8 Trading Days
9.44%
Link
LONG
Jan 8. 2020
41.55
Jan 23. 2020
45.85
10 Trading Days
10.36%
Link
LONG
Feb 3. 2020
45.49
Feb 24. 2020
50.27
14 Trading Days
10.51%
Link
LONG
Apr 16. 2020
33.26
May 1. 2020
37.76
11 Trading Days
13.52%
Link
LONG
Nov 6. 2020
30.01
Nov 23. 2020
34.99
11 Trading Days
16.58%
Link
LONG
Dec 8. 2020
37.37
Dec 31. 2020
45.13
16 Trading Days
20.77%
Link
Company Information
Stock Symbol
RGNX
Exchange
NasdaqGS
Company URL
http://www.regenxbio.com
Company Phone
240-552-8181
CEO
Kenneth T. Mills
Headquarters
Maryland
Business Address
9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE, MD 20850
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001590877
About

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Description

Developing gene therapies for rare diseases with a proprietary delivery platform.